NASDAQ:ENSC Ensysce Biosciences Q4 2025 Earnings Report $0.42 +0.02 (+6.08%) Closing price 04:00 PM EasternExtended Trading$0.40 -0.02 (-3.58%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ensysce Biosciences EPS ResultsActual EPS-$0.75Consensus EPS -$1.26Beat/MissBeat by +$0.51One Year Ago EPSN/AEnsysce Biosciences Revenue ResultsActual Revenue$1.88 millionExpected Revenue$0.50 millionBeat/MissBeat by +$1.38 millionYoY Revenue GrowthN/AEnsysce Biosciences Announcement DetailsQuarterQ4 2025Date3/30/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsEnsysce Biosciences' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Ensysce Biosciences Earnings HeadlinesReviewing Ensysce Biosciences (NASDAQ:ENSC) and Hypermarcas (OTCMKTS:HYPMY)September 29, 2026 | americanbankingnews.comEnsysce Biosciences Corporate Event Calendar | NASDAQ:ENSCSeptember 9, 2026 | benzinga.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 5 at 1:00 AM | Banyan Hill Publishing (Ad)Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks TranscriptAugust 18, 2026 | seekingalpha.comENSC sets itself up nicely for critical stageAugust 14, 2026 | msn.comEnsysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing - The Globe and MailAugust 7, 2026 | theglobeandmail.comSee More Ensysce Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ensysce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ensysce Biosciences and other key companies, straight to your email. Email Address About Ensysce BiosciencesEnsysce Biosciences (NASDAQ:ENSC) is a clinical-stage biotechnology company developing prescription medicines designed to improve the safety of opioid pain treatment. The company focuses on technologies intended to reduce the potential for opioid abuse, misuse, and overdose while preserving analgesic activity. Ensysce’s lead program is PF614, an investigational extended-release oxycodone prodrug being developed with its Trypsin-Activated Abuse Protection (TAAP) technology. The platform is designed to limit the release of active oxycodone when the product is manipulated for non-oral use. Ensysce has also been developing PF614-MPAR, a combination product intended to pair PF614 with an overdose-protection component. The company’s pipeline is aimed primarily at the prescription pain-management market and reflects its broader focus on creating abuse-deterrent and overdose-resistant opioid formulations. Ensysce Biosciences is headquartered in San Diego, California, and its programs remain subject to clinical development and regulatory review.View Ensysce Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
